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Aims B-type natriuretic peptide (BNP)–natriuretic peptide receptor A (NPR-A) receptor signalling inhibits cardiac sympa-
thetic neurotransmission, although C-type natriuretic peptide (CNP) is the predominant neuropeptide of the nerv-
ous system with expression in the heart and vasculature. We hypothesized that CNP acts similarly to BNP, and
that transgenic rats (TGRs) with neuron-specific overexpression of a dominant negative NPR-B receptor would




Mean arterial pressure and heart rate (HR) were significantly (P< 0.05) elevated in freely moving TGRs (n¼ 9)
compared with Sprague Dawley (SD) controls (n¼ 10). TGR had impaired left ventricular systolic function and
spectral analysis of HR variability suggested a shift towards sympathoexcitation. Immunohistochemistry demon-
strated co-staining of NPR-B with tyrosine hydroxylase in stellate ganglia neurons. In SD rats, CNP (250 nM, n¼ 8)
significantly reduced the tachycardia during right stellate ganglion stimulation (1–7 Hz) in vitro whereas the response
to bath-applied norepinephrine (NE, 1 lM, n¼ 6) remained intact. CNP (250 nM, n¼ 8) significantly reduced the
release of 3H-NE in isolated atria and this was prevented by the NPR-B antagonist P19 (250 nM, n¼ 6). The neuro-
nal Ca2þcurrent (n¼ 6) and intracellular Ca2þ transient (n¼ 9, using fura-2AM) were also reduced by CNP in
isolated stellate neurons. Treatment of the TGR (n¼ 9) with the sympatholytic clonidine (125 mg/kg per day) signifi-
cantly reduced mean arterial pressure and HR to levels observed in the SD (n¼ 9).
....................................................................................................................................................................................................
Conclusion C-type natriuretic peptide reduces cardiac sympathetic neurotransmission via a reduction in neuronal calcium sig-
nalling and NE release through the NPR-B receptor. Situations impairing CNP–NPR-B signalling lead to hyperten-
sion, tachycardia, and impaired left ventricular systolic function secondary to sympatho-excitation.
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Natriuretic peptides (NPs) comprise a family of structurally related,
but genetically distinct peptide hormones, including atrial NP (ANP),
brain/B-type NP (BNP), and C-type NP (CNP).1 ANP and BNP levels
are greatly elevated in heart failure,2 and are also negative prognostic
indicators during hypertension,3 and acute ischemic stroke.4 They are
both predominantly synthesized in the cardiac chambers, and released
upon cardiac wall stretch into the circulation, modulating vascular tone,
permeability, renal function, and the renin–angiotensin system.1,5 Locally
within the heart, ANP and BNP can also act directly on cardiomyocytes,
protecting against cardiac hypertrophy and heart failure.3–7 More
recently, BNP has been shown to inhibit local cardiac sympathetic neu-
rotransmission by reducing calcium signalling in post-ganglionic sympa-
thetic neurons which may be beneficial during chronic heart failure.6
C-type NP plasma concentrations are comparatively low compared
with ANP/BNP, but they also increase during heart failure,8,9 and there-
fore CNP may also play an important role in the pathophysiology of this
condition. CNP was originally identified in porcine brain and is consid-
ered the predominant NP in the nervous system,10–12 although it is also
expressed locally within the heart and coronary vasculature.13 However,
it is not known whether CNP, like BNP, is able to modulate cardiac sym-
pathetic neurotransmission. The NPs mediate their actions through cell
surface receptors.14 ANP and BNP bind specifically to natriuretic peptide
receptor A (NPR-A), whereas CNP specifically activates NPR-B. Both
receptors have intrinsic guanylyl cyclase activity, resulting in an increase
in cGMP15 and protein kinase G signalling.16–18 Although the cardiac phe-
notypes of NPR-A signalling have been well studied within transgenic
and disease models, little is known about the cardiac signalling of NPR-B.
NPR-B homozygous knockout mice display seizures, female sterility,
and priapism, making them un-suitable for detailed cardiovascular
phenotyping.19,20 To overcome this limitation, we generated a transgenic
rat (TGR) with neuron-specific overexpression of a dominant-negative
NPR-B mutant (NPR-BDKC) under the control of a promoter for
neuron-specific enolase (NSE-NPR-BDKC).18 We hypothesized that this
TGR would display elevated sympathetic nerve activity compared with
its SD control in vivo, and investigated the cellular mechanisms by which
CNP influences cardiac sympathetic neurotransmission in the SD rat
in vitro.
2. Methods
A detailed methods section can be found in the Supplementary material
online. Experiments conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 2011) and the Animals (Scientific
Procedures) Act 1986 (UK). Experiments were performed under British
Home Office Project License PPL 30/2360 and the German License
LaGeSo G0343/08. For all in vitro experiments, rats were euthanized by
approved home office schedule 1 method of overdose by pentobarbital
(0.3 mL, 100 g) under deep anaesthesia (3% isoflurane and 97% oxygen).
2.1 Statistical analysis
Data are presented as mean 6 S.E.M. (standard error of the mean).
Differences between two groups were evaluated by using an unpaired
Student’s t-test. Where multiple interventions are made in each of the
two groups, a two-way analysis of variance followed by Sidak’s multiple
comparison test was performed using PRISMVR software (PRISM,
GraphPad Software Inc, San Diego, California, USA). The significance
level was accepted at P< 0.05.
3. Results
3.1 Hypertension, tachycardia, and evidence
for autonomic dysfunction in the TGR
Telemetric blood pressure measurement in 4-month-old conscious rats
revealed an elevated mean (MAP) and diastolic blood pressure in TGR
(n¼ 10) compared with SD controls (n¼ 9). Furthermore, heart rate
(HR) was significantly elevated in the TGR group (Figure 1A).
Transthoracic echocardiography of TGR (n¼ 9) revealed significantly
reduced left ventricular systolic function (LVSF) indicated by a reduced
ejection fraction, reduced fractional shortening, and increased left
ventricular end-systolic diameter, whereas left ventricular end-
diastolic dimensions were similar to those of SD (n¼ 9) wild-type ani-
mals (Table 1).
To investigate the influence of neural NPR-B signalling on cardiovascu-
lar autonomic control, spectral analysis of blood pressure and heart rate
variability (HRV) was performed. Overall HRV as measured by the
standard deviation of the NN interval was reduced in the TGR com-
pared with the wild-type although the standard deviation of systolic
blood pressure (SBP) variability was similar (Figure 1G and H). The low
frequency (LF) and high frequency (HF) peaks of HRV and the LF peak of
SBP as well as the LF/HF ratio were higher in the TGR compared with
SD controls. Cross-spectral analysis revealed decreased baroreflex sen-
sitivity in the low frequency (BRS-LF) band in the TGR compared with
SD controls (Figure 1B–F). This suggests an imbalance of the autonomic
nervous system with a shift to higher levels of sympathetic drive relative
to parasympathetic activity. In keeping with this observation, plasma
renin activity and concentration as well as plasma angiotensin II concen-
trations were also significantly increased in the TGR compared with SD
controls (Table 2).
3.2 CNP reduces the HR response to
sympathetic stimulation by inhibiting
norepinephrine release
To evaluate whether CNP could modulate cardiac sympathetic neuro-
transmission, we used isolated atria right stellate ganglion preparations
from SD rats. After equilibration the beating rate was 263 6 7 bpm
(n¼ 29) and CNP (50–250 nM) did not significantly change this baseline.
The HR response to stimulation of the right stellate ganglion was
unchanged by 50 (n¼ 7) or 100 nM CNP (n¼ 8) but was significantly
reduced by CNP at 250 nM (n¼ 8), with a trend to reduce the response
at 500 nM (n¼ 6) (Figure 2A and B). However, CNP did not affect the HR
response to exogenous norepinephrine (NE 1 mM, controlþ125 6 20
bpm, 500 nM CNPþ115 6 15 bpm, n¼ 6). This suggests that CNP
reduces the HR response to sympathetic stimulation via a neural mecha-
nism. We therefore directly measured NE release and reuptake to see
whether CNP modulates these processes. CNP (250 nM) significantly
reduced the release of 3H labelled NE to field stimulation in isolated right
atria from the SD rat (n¼ 8) (Figure 3A and B), although this could be pre-
vented by the NPR-B antagonist P19 (250 nM, n¼ 6). CNP had no effect
on the function of the NE reuptake transporter when measured in iso-
lated sympathetic stellate ganglia neurons (control, n¼ 19; CNP 250 nM,
n¼ 12) (Figure 3C and D). The NE content of unstimulated stellate ganglia
was also unchanged by 250 nM CNP (control, n¼ 6, 1.25 6 0.05 vs.

















.CNP, n¼ 6, 1.36 6 0.66 pmol/mg tissue) suggesting that CNP did not
modulate NE synthesis. In summary, these data provide evidence for a
sympathoinhibitory action of CNP acting on post-ganglionic neurons
from the right stellate ganglion to reduce sympathetic neurotransmission.
3.3 Endogenous NPR-B expression and
modulation of neuronal calcium handling
by CNP in stellate sympathetic neurons
Immunohistochemistry revealed that endogenous NPR-B is colocalized
to tyrosine hydroxylase containing sympathetic neurons cultured from
the stellate ganglia of SD rats (Figure 4A). Within isolated stellate sympa-
thetic neurons CNP (250 nM, n¼ 6) significantly reduced the magnitude
of the neuronal calcium current measured by patch clamp recording
(Figure 4B and C). CNP (100 nM, n¼ 6 and 250 nM, n¼ 9) also signifi-
cantly reduced the magnitude of depolarization-induced intracellular cal-
cium transients (Figure 4D and E).
3.4 Effect of reducing sympathetic
neurotransmission in the TGR
To test whether increased sympathetic activity is responsible for the







Figure 1 Telemetric measurements and powerspectral analysis in conscious SD wildtype (WT, n¼ 9) and pNSE-NPR-BDKC transgenic (TG, n¼ 10)
rats. (A) MAP, SBP, and diastolic blood pressure (DBP) as well as HR in SD and TG rats. (B–D) Cumulative spectral moduli of HRV and SBP in the LF and HF
bands in control and NSE-NPR-BDKC TG rats. (E, F) Spontaneous BRS-LF and calculated as the gain of the LF-SBP. (G, H) Overall HRV was assessed as the
standard deviation of the NN interval (SDNN) along with the standard deviation of systolic blood pressure (SD-SBP) (*P< 0.05, **P< 0.01 transgene vs.
SD wild-type).

































transgenic animal, the TGR were treated with the sympatholytic drug
clonidine (125 mg/kg  day). Clonidine treatment significantly reduced
MAP and HR to the level detected in SD wild-type animals. After wash-
out of clonidine, haemodynamic parameters were indistinguishable from
baseline values (Figure 5A and B), indicating increased sympathetic activity
in NSE-NPR-BDKC TGR (n¼ 9, both groups).
4. Discussion
Dysregulation of the autonomic nervous system has previously been
implicated in human21–24 and animal models of cardiovascular disease
and heart failure.25–28 We therefore investigated the impact of reduced
neuronal NPR-B signalling on hemodynamic parameters. We generated
a novel rat model with neuron-specific overexpression of a dominant-
negative mutant of NPR-B.18 The model allowed us to overcome the
limitations related to knockout of the NPR-B gene and demonstrated for
the first time that NPR-B and its ligand CNP are involved in the regula-
tion of cardiovascular function via direct sympathoinhibition. We studied
the function of neuronal NPR-B on the autonomic regulation of the car-
diovascular system in vivo in the TGR, and the in vitro effect of CNP on
SD wild-type tissue. Our novel findings were that CNP signalling via the
NPR-B receptor is sympathoinhibitory via a direct action on stellate sym-
pathetic neurons. CNP reduces the neuronal calcium current and intra-
cellular calcium transient to inhibit NE release, although CNP does not
alter NE re-uptake via the NET1 transporter, or NE synthesis.
Telemetric measurement in conscious rats revealed increased mean
arterial blood pressure, HR, and changes in HRV consistent with
increased sympathetic relative to parasympathetic activity in the trans-
genic model. Conversely, the HR response to stimulation of the right
stellate ganglion in vitro was significantly reduced by CNP in wild-type SD
rats, although CNP did not alter the HR response to NE, suggesting that
CNP acts pre-synaptically to inhibit sympathetic neurotransmission
rather than post-junctionally on cardiomyocyte b1 receptor signalling.
This was confirmed by a reduced release of tritiated NE upon field stimu-
lation in the isolated right atria by CNP, an effect that could be prevented
by an NPR-B antagonist. These findings mirror observations made with
BNP and NPR-A signalling which can also reduce postganglionic sympa-
thetic release of NE in the heart.6
Immunohistochemical studies confirmed the presence of NPR-B on
stellate sympathetic neurons of the SD rat. The reduced tritiated NE
release is coupled with no change in the rate of action of the NE reup-
take transporter; therefore, increased NET activity is not responsible for
the reduced neurotransmitter release at the cellular level in response to
NPR-B activation. Moreover, within isolated stellate sympathetic neu-
rons we have shown that CNP reduces neuronal calcium current and
depolarization-induced intracellular calcium transients. NPR-B is pro-
posed to act via particulate guanylyl cyclase, resulting in an increase in
cGMP15 and protein kinase G signalling,16–18 leading to the inhibition
Ica.
29 This pathway has previously been studied in relation to NPR-A/
BNP signalling in stellate sympathetic neurons where cGMP–protein kin-
ase G-dependent inhibition of calcium handling and neurotransmission is
limited by PDE2A.6 Our results demonstrate a direct effect for CNP sig-
nalling on postganglionic stellate sympathetic neurons to reduce
......................................................................................................
Table 1 Transthoratic echocardiography in TGR (TG;
n¼ 9) and SD wild type (WT; n¼ 9)
LVEDD (mm) LVESD (mm) FS (%) EF (%)
WT 8.3 6 0.2 4.8 6 0.2 42 6 2 72 6 2
TG 8.2 6 0.2 5.6 6 0.1** 32 6 1*** 58 6 2***
LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-sys-
tolic dimension; FS, fractional shortening; EF, ejection fraction. **P< 0.01,
***P< 0.001.
......................................................................................................
Table 2 Plasma renin activity (PRA) and concentration
(PRC) and plasma angiotensin II concentration (ATII) in
TGR (TG, n¼9) and SD wild type (WT, n¼10)
PRA (mg/mL 3 h) PRC (ng/mL) ATII (pg/mL)
WT 8.1 6 1.9 11.8 6 2.4 104 6 14
TG 15.8 6 2.4* 24.6 6 3.5** 156 6 10*
*P< 0.05, **P< 0.01.
A
B
Figure 2 (A) Representative raw data traces showing the effect of
250 nM CNP (grey) compared with control (black) on the HR response
to stimulation of the right stellate ganglion at 1–7 Hz in isolated atria-
stellate preparations from the SD rat in vitro. (B) Group mean data
showing the effect of CNP at 50 (n¼ 7), 100 (n¼ 8), 250 (n¼ 8), and
500 (n¼ 6) on the tachycardia to right stellate stimulation at 1–7 Hz
(**P< 0.01 control vs. CNP).
































.neurotransmission. Others have demonstrated that CNP can increase
tyrosine hydroxylase mRNA expression and catecholamine content via
a cGMP-dependent pathway in bovine adrenal chromaffin cells.30 We
therefore also measured the action of CNP on NE synthesis, although
we found no effect on NE content of unstimulated stellate ganglia.
Previously, a modulatory effect of CNP on sympathetic cotransmis-
sion in the rat isolated tail artery has also been shown,31 and we cannot
exclude the possibility that vasoconstriction may contribute to the
hypertensive phenotype of the neural NPRB-TGR due to increased vas-
cular sympathetic neurotransmission and/or increased activation of the
renin–angiotensin system by the sympathetic nervous system.
Within the TGR the neural action of NPR-B signalling was confirmed
by the administration of the sympathetic blocker clonidine.32 Clonidine
supresses sympathetic outflow at least in part by stimulating central pre-
synaptic a2 receptors to reduce NE release.
32 Clonidine reduced mean
arterial blood pressure and HR of the transgenic model back to that of
wildtype, before returning to the baseline of the TGR after a washout
period. This reinforces the principle that the hypertension and tachycar-
dia present in the TGR are due to an increased sympathetic drive. This
hypothesis is further supported by observations showing that NPR-B is
the predominant NPR in the heart, and is down-regulated in heart
failure.33,34 Furthermore, previous studies have shown that cardiac cells
are actively involved in the production of CNP and cardiomyocyte-
specific overexpression in a transgenic mouse model prevented cardiac
hypertrophy induced by myocardial infarction.35,36 It is interesting to
note that a ubiquitous overexpression of the dominant negative NPR-B
mutant leads to concentric left ventricular hypertrophy and increased
sympathetic activity,18 whereas we report here that neural-specific over
expression of the mutant leads to impaired LVSF without hypertrophy.
Cardiac myocyte NPR-B signalling may therefore inhibit cardiac hyper-
trophy as has been demonstrated for NPR-A,37 but this might be delete-
rious in the presence of sympathetic hyperactivity which may then
promote hypertensive heart failure. The impaired LVSF observed in the
TGR may cause further sympatho-excitation through activation of arte-
rial baroreceptors as heart failure progresses. If the sympathoexcitation
in the TGR was purely secondary to systolic heart failure, it would be
expected that the TGR would have normal or low blood pressure. The
fact that blood pressure is paradoxically elevated in the TGR points to
sympathoexcitation being the main driver of the systolic heart failure
rather than the other way around.
We also observe increased plasma renin levels and activity, and
higher circulating levels of angiotensin II in the TGR which can be
A B
C D
Figure 3 (A) Representative raw data trace showing 3H efflux in counts per minute over time and the effect of 250 nM CNP on the evoked release of 3H-
NE (S2) in response to field stimulation (5 Hz) compared with control (S1) in right atria from the SD rat. (B) Group data (including mean and standard error)
as a dot plot showing a significantly reduced release of 3H-NE (percentage increase from baseline) in response to field stimulation following addition of
250 nM CNP (n¼ 8 atria). The action of CNP is lost in the presence of the NPR-B antagonist P19 (250 nM, n¼ 6 atria). (C) Raw data trace showing increase
in fluorescence (au) over time, of a stellate sympathetic neuron in a solution containing the NE reuptake transporter (NET) assay. The control slope is repre-
sented in black and the slope after addition of 250 nM CNP in black with grey fill. The fluorescence increase is blocked by the NET inhibitor desipramine
(DMI, 1 lM, in grey). (D) Group data (including mean and standard error) as a dot plot showing no change in NET activity between CNP 250 nM and control.
DMI blocks fluorescence uptake in both groups. (Control, n¼ 19 neurons; CNP n¼ 12 neurons). *P< 0.05 control vs. CNP, ***P< 0.001 vs. control or
CNP.





















both caused by renal sympathetic stimulation and by renal hypoper-
fusion during heart failure. Angiotensin II promotes the release of NE
from cardiac sympathetic nerve terminals,27 so this may also act as a
positive feedback mechanism increasing sympathetic drive and wor-
sening subsequent heart failure. We think it highly unlikely that the
transgene itself is acting directly on cardiac myocytes to induce a car-
diomyopathy as we have previously demonstrated by reverse
transcriptase-polymerase chain reaction that the transgene is present
in neuronal tissue only and not heart, lung, aorta, or kidney.38 We
have observed impaired LVSF and abnormal HRV in the TGR com-
pared with the SD control at 8 weeks of age, but it is not known
whether the abnormal HRV precedes the left ventricular dysfunction
in the immediate postnatal period.
5. Limitations
Although our studies have focused on the role of CNP in modulating the
peripheral sympathetic nervous system at the level of the heart, CNP is
the major NP in the central nervous system and cerebrospinal fluid.12,39
NPR-B expression has been observed in a broad range of brain regions,
including brainstem nuclei involved in autonomic function.40,41 We
therefore cannot exclude a central action of CNP in the NPR-B TGR
whereby CNP acts to inhibit pre-ganglionic sympathetic outflow. NPR-B
has also been reported in glial cells in the central nervous system42
although we only observe NPR-B staining in TH positive neurons in the
stellate which are morphologically distinct from glial cells or fibroblasts.




Figure 4 (A) Immunohistochemistry showing tyrosine hydroxylase (TH) staining with texas red in cultured sympathetic neurons of the right stellate gan-
glia from SD rats also staining positive for the NPR-B in green (fluorescein) Nuclear staining is shown with DAPI in blue and co-localization is demonstrated
by overlap of staining in yellow (20 magnification). (B) Representative whole cell calcium current density traces with (grey S2) or without (black) 250 nM
CNP. Current evoked by test pulses from a holding potential of 90 to 10 mV. (C) Mean current density–voltage relations in the presence or absence of
250 nM CNP (n¼ 6). (*P< 0.05, **P< 0.01 control vs. CNP). (D) Representative raw data trace of calcium transients induced by 50 mM KCl (30 s) in a sin-
gle stellate sympathetic neuron in control (black S1) and in the presence of 100 or 250 nM CNP (grey). (E) Group data (including mean and standard error)
as a dot plot showing a significant reduction in KCl-evoked calcium transients in isolated stellate neurons from the SD rat after 100 nM (n¼ 6) and 250 nM
(n¼ 9) CNP. *P< 0.05, **P< 0.01 vs. control.






























































..guinea pig BNP and also CNP can facilitate vagal neurotransmission,
thereby inducing bradycardia via a cGMP-dependent mechanism, com-
parable to NO.43 However, in SD rats we find no NPR-B staining in chol-
inergic neurons in the right atria (data not shown).
Heart rate variability is a controversial method of providing a quantita-
tive measure of the contribution of the individual branches of the auto-
nomic nervous system, particularly when the LF/HF ratio is viewed in
isolation (e.g. see the point–counterpoint debate in the Journal of Applied
Physiology44). However, we report HRV data for LF and HF bands individ-
ually as well as a ratio, and also present data on spontaneous BRS-LF and
calculated as the gain of the transfer function between systolic blood
pressure (SBP) and pulse interval (LF-SBP). We cautiously conclude that
all of these indices, together with the changes in mean arterial pressure
(MAP) and HR, are evidence for a change in autonomic balance and are
careful not to attribute this solely to a particular branch of the autonomic
nervous system based on these data alone. We perform further experi-
ments on isolated hearts and stellate neurons, measure plasma renin/
angiotensin levels, and use clonidine treatment in vivo to extend these
findings.
The 3H method of quantifying NE release also has limitations. We
deliberately chose the same stimulation parameters used in the isolated
atrial/stellate preparation which produced physiological increases in HR
(5 Hz, 20 V, 1 ms pulse duration), although this will not exactly mimic the
in vivo situation. The measured release of NE has been shown to be fre-
quency dependent and also dependent on extracellular calcium and
blocked by N-type calcium channel blockers.45
Although we clearly show the action of exogenous CNP on cardiac
neurotransmission in SD controls, we have not demonstrated an
impaired action of CNP on neuronal calcium signalling, NE release, and
re-uptake in the TGR. Although an NPR-B antagonist prevents that
action of CNP on NE release in the SD control, it is possible that com-
pensatory upregulation of the NPR-A receptor or the clearance recep-
tor NPR-C influences the phenotype of the TGR. We have however
previously shown that the NPR-B TGR has impaired generation of
cGMP in neuronal tissue in response to CNP, whereas cGMP generation
via NPR-A remains intact.38 In addition to this, inhibiting sympathetic
drive with clonidine normalizes the difference in blood pressure and HR
between the NPR-B TGR and the SD providing some evidence for its
role in producing these differences.
The levels of circulating CNP are also far lower than the 100 nM (and
above) used in our in vitro experiments. However, the circulatory levels
of most hormones are orders of magnitude lower than local concentra-
tions at neural release sites and the concentrations of exogenous ligand
that produce responses in isolated tissues. For example, circulatory NE
is in the low nanomolar range,46 whereas exogenous concentrations
required for maximal stimulation of isolated cardiac tissue are in the
micromolar range.27
In summary, our study provides the first evidence that impaired neu-
ronal NPR-B signalling leads to sympathoexcitation, hypertension, tachy-
cardia, and impaired LVSF. The findings suggest that activation of NPR-B
or its downstream signalling pathways might be beneficial in the treat-
ment of cardiovascular diseases associated with autonomic dysfunction.
We believe that these observations could lead to further therapeutic
avenues.
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